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Abstract
Background: Helicobacter pylori has been recognized as the most common pathogen of human gastroduodenal tract and it has
been suggested that adhesins, including HopQ and SabA, are associated with the organism’s virulence.
Objectives: The current study aimed at determining the frequency of hopQI, hopQII, and sabA genes among H. pylori isolates from
patients with gastroduodenal disorders in Shahrekord, Iran.
Methods: Gastric corpus samples were obtained from 150 symptomatic patients admitted to the endoscopy unit at gastroenterol-
ogy clinic. After DNA extraction from all corpus samples, H. pylori molecular confirmation and genotyping was performed by the
polymerase chain reaction (PCR), using specific primers for glmM, 16SrRNA and hopQ, sabA genes, respectively.
Results: The hopQI, hopQII, and sabA genes were found in 74 (49.3%), 59 (39.3%), and 43 (28.7%) cases, respectively. The hopQI gene was
detected in 75% of patients with gastric cancer (GC), 42.4% with chronic gastritis (CG), and 57.4% with peptic ulcer disease (PUD). The
hopQII among patients with GC, CG, and PUD was also detected in 50%, 38.8%, and 39.3%, respectively. Moreover, sabA was diagnosed
in 50% of patients with GC, 29.4% with CG, and 26.2% with PUD.
Conclusions: No significant association was observed between hopQI, hopQII, and sabA genes with clinical outcomes.
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1. Background
Helicobacter pylori as microaerophilic and Gram-
negative spiral shaped bacteria, are strongly associated
with chronic gastritis (CG), peptic ulcer disease (PUD), and
gastric cancer (GC) (1). In all patients, the infection can
cause gastritis, yet only 10% to 15% will develop clinical
signs (1, 2). Binding of H. pylori to the gastric epithelia,
can result in the colonization, evasion from the immune
system, and transfer of virulence factors to the gastric
cells.
Helicobacter pylori outer membrane proteins (OMPs)
can play an important role in binding to the gastric epithe-
lia (1). About 4% of the genome is responsible for encoding
OMPs, including SabA, AlpA and B, BabA, OipA, and HopQ
(OMP 27) (1, 3-6). HopQ is divided to two families, HopQI
and HopQII, which have amino acid sequence homology
between 61% and 72% (7). Although the function of this pro-
tein is unknown, it has been suggested that it is involved in
organism colonization, adhesion, and progress of peptic
ulceration (7-9). The distribution of hopQI andhopQII genes
varies in different populations and geographic regions (10-
12). The hopQ shows a high degree of genetic diversity and
H. pylori hopQI is more common in patients with peptic ul-
cer. Moreover, HopQI and HopQII are mostly present in
cag A+ strains (13). On the other hand, SabA is a sialic acid-
binding protein and can mediate binding of H. pylori to
gastric mucosa cells. Sialyl-Lewis x/a (sLeX and sLea) anti-
gens act as adhesin receptors for the SabA protein.
Sialylated glycoconjugates are found in small amounts
in the stomach of healthy individuals yet in the presence
of H. pylori infection, the expression of these antigens, es-
pecially sLea, are associated with gastric malignancies in
both developed and developing countries. This issue repre-
sents the important role of SabA in gastric atrophy and gas-
tric cancer. Therefore, more studies on SabA, particularly in
developing countries, is suggested (14, 15). The association
of different genotypes of H. pylori with clinical outcomes
varies in different populations. Hence, investigation of pu-
tative virulence factors is crucial to provide useful clinical
data in medical practice.
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2. Objectives
Since there have been limited published epidemio-
logic studies on the prevalence of hopQ and sabA in H. py-
lori strains isolated from patients with gastrointestinal dis-
orders in Iran, the present study aimed at evaluating the
frequency of these genes among H. pylori isolates from pa-
tients with gastroduodenal disorders in an Iranian symp-
tomatic population.
3. Methods
3.1. Ethics Statement
This study was approved by the Ethics Committee of
Shahrekord University of Medical Sciences (EC = 92-11-31).
3.2. Patients, Endoscopy and Biopsies
In this cross-sectional study, conducted between
March 2013 and April 2015, 150 H. pylori-positive patients,
who underwent upper gastrointestinal endoscopy for a
variety of indications at the Endoscopy Services of Hajar
Hospital in Shahrekord, center of Iran, were included.
Based on endoscopic and histological findings, the par-
ticipants were classified to chronic gastritis (CG = 85),
peptic ulcer disease (PUD = 61), and gastric cancer (GC
= 4) groups. Some samples were taken from previously
performed studies (16, 17). Written informed consent was
obtained from all patients. Patients, who had undergone
anti-H. pylori eradication therapy within the past three
months, were excluded. During gastroscopy, biopsy sam-
ples were taken from the corpus for rapid urease test (RUT)
and DNA extraction.
3.3. Rapid Urease Test (RUT)
For each patient, corpus samples were taken and tested
for the presence of urease enzyme. The campylobacter-like
organism (CLO) test (Romania) was used in this study. Af-
ter 10 to 15 minutes at room temperature, if H. pylori urease
was present in the tissue sample, it changed the gel from
yellow to bright magenta.
3.4. Genomic DNA Extraction and Polymerase Chain Reaction
(PCR)
The phosphate buffer saline (pH = 7.2) microtubes con-
taining corpus biopsies for DNA extraction were sent to
the Cellular and Molecular Center, Shahrekord University
of Medical Sciences. Genomic DNA was extracted using
the DNA extraction kit (BioFlux Co., Japan), according to
the manufacturer’s instructions. For H. pylori, molecular
diagnosis at the species level (glmM and 16S rRNA), and
for the presence of hopQI, hopQII and sabA genes, PCR as-
says were performed by previously described primers (7,
18, 19). Each PCR amplification was performed in a reac-
tion volume of 25 µL, containing 1 × PCR buffer, 200 ng
DNA, 4 mM MgCl2, 1.6 mM dNTP, 0.02 U Taq DNA polymerase
and 0.16 pM primer (for hopQI) and 300 ng DNA, 4 mM
MgCl2, 1.6 mM dNTP, 0.02 U Taq DNA polymerase, and 0.2
pM primer (for hopQII). To detect sabA, 200 ng DNA, 6 mM
MgCl2, 3.2 mM dNTP, 0.02 unit Taq DNA polymerase, and 0.2
pM primer was used. The amplification of individual genes
was done in a thermocycler (Corbett Research, Australia),
as described previously (10, 19, 20). Amplicons were ana-
lyzed on 1% agarose gel and stained by the ethidium bro-
mide (0.5µg/mL) for sabA and 6% polyacrylamide gel with
TBE 5× forhopQI andhopQII genes, and examined under UV
illumination (Figure 1).
3.5. Data Analysis
The Chi-square (χ2) and Fisher’s exact tests were used
for analysis of significant differences between the studied
virulence genes with the clinical outcome results using the
SPSS software (version 22.0; IBM Co., Armonk, NY, USA). The
results of demographic and clinical manifestations were
presented as descriptive statistics in terms of relative fre-
quency. P values of < 0.05 were considered statistically sig-
nificant.
4. Results
In the current study, 150 H. pylori strains obtained from
patients (85 females and 65 males, ranging in age from 15
to 85 years with a mean age of 43 years, which were cate-
gorized to three groups, including patients < 30, between
30 and 50, and > 50 years old) with gastroduodenal disor-
ders after confirmation by RUT and PCR (for detection of
glmM and 16S rRNA genes), were evaluated for the presence
of hopQI,hopQII and sabAgenes. ThehopQI,hopQII, and sabA
genes were detected in 74 (49.3%), 59 (39.3%), and 43 (28.7%)
of the isolates, respectively (P > 0.05). The distribution of
these genes in CG, PUD, and GC cases, were as follows: hopQI
(42.4%, 57.4%, and 75%), hopQII (38.8%, 39.3%, and 50%) and
sabA (29.4%, 26.2%, and 50%). No significant difference (P >
0.05) was observed between age or gender and clinical out-
come (Tables 1 and 2). The association between disease type
and the presence of hopQI, hopQII and sabA genes was also
not significant (P > 0.05).
5. Discussion
The present study evaluated the frequencies of H. py-
lori hopQI, hopQII, and sabA genes among patients with gas-
troduodenal diseases in Shahrekord, Iran. The hopQI gene
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Figure 1. Agarose gel electrophoresis of sabA and polyacrylamid gel of hopQI and hopQII genes in H. pylori isolates. A, H. pylori sabA: lane 1: 1kb DNA ladder marker, lanes 2 - 4
(1800 bp): sabA positive strains, and lane 5 is negative for sabA. B, H. pylori hopQI: lane 1: 100 bp DNA ladder marker, lanes 3 - 5 and 7 (525 bp): hopQI positive strains and lanes 2
and 6 are negative for hop QI. C, H. pylori hopQII: lane 1: 100 bp DNA ladder marker, lanes 3 - 5 and 7 - 8 (430 bp): hopQII positive strains, and lanes 2 and 6 are negative for hopQII.
Table 1. Distribution of Different Clinical Diseases According to Patients’ Gendera , b
Gender
Disease Group Total
Group 1 Group 2
Female 29 (44.6) 56 (65.9) 85 (56.7)
Male 36 (55.4) 29 (34.1) 65 (43.3)
Total 65 (100) 85 (100) 150 (100)
aValues are expressed as No. (%).
bGroup 1: Patients with peptic ulcer disease and gastric cancer, group 2: pa-
tients with chronic gastritis.
was predominant (49.3%) in comparison with hopQII and
sabA genes with frequencies of 39.3% and 28.7%, respec-
tively. Host’s genetics, environmental factors, such as diet,
and H. pylori virulence determinants are associated with
the severity of clinical outcomes (21, 22). Genotypic analy-
sis of H.pylori is also a useful method in screening of gastric
diseases (20). In the recent years, the role of H. pylori OMPs,
such as hopQ and sabA, in developing of digestive diseases
have been investigated. Therefore, the association of viru-
lence genes with clinical outcome needs to be further in-
Table 2. Distribution of Different Clinical Diseases According to Patients’ Agea , b
Age Disease Group Total
Group 1 Group 2
Group 1 17 (26.2) 18 (21.2) 35 (23.3)
Group 2 31 (47.7) 45 (52.9) 76 (50.7)
Group 3 17 (26.2) 22 (25.9) 39 (26)
aValues are expressed as No. (%).
bAge group 1: patients less than 30 years old, age group 2: patients between 30
to 50 years old, age group 3: patients more than 50 years old, disease group 1:
patients with peptic ulcer disease and gastric cancer, disease group 2: patients
with chronic gastritis.
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vestigated in clinical practice. It has shown that hopQ can
be a candidate adhesin to gastric epithelium cells (8).
The frequencies of hopQI and II alleles vary depending
on geographic regions. Previous studies in Western and
Eastern countries have shown that there is a higher preva-
lence of hopQI than hopQII. The prevalence of hopQI and
hopQII genes in the United States and East Asian countries
were reported as 55.5%, 30.9% and 88.8%, 0.7%, respectively
(10). Moreover, this frequency for hopQI among Colom-
bian and Italian patients was reported as 72% and 29%, re-
spectively (11, 12). The current results (49.3% for hopQI and
39.3% for hopQII) are similar with a study conducted in the
United States (10). Indeed, in the study of Ohno et al. (9)
among Asian and Western population, no significant asso-
ciation was observed between hopQ genotypes and clini-
cal outcome. In the first ever study conducted in Iran, the
frequency of hopQI (33%) was mentioned lower than hopQII
(52%), and the hopQII genotype was found to be associated
with gastric cancer (20). The reported results are in con-
trast with the current study, so that no association was
found between gastrointestinal diseases and hopQ alleles
(P > 0.05). The current findings are consistent with the re-
sults of two other studies from Iran (23, 24).
Due to the absence of sLeX in normal gastric epithelia,
the sabA can be related to the H. pylori chronic persistence
and severe clinical outcomes, such as gastric cancer (14,
25). The present data (28.7%) compared to studies in Taiwan
(80%), France (86%), and Netherland (93%), revealed a much
lower rate (26-28). The sabA frequency among Japanese pa-
tients from different population and times, was also found
to be 81% and 91%, respectively (29, 30). Yamaoka et al. in the
United States reported that sabA frequency in patients with
gastritis, duodenal ulcer and gastric cancer was 66%, 44%,
and 70%, respectively, and a significant association was es-
tablished between sabA and gastritis and gastric cancer
(31).
In three previous studies from Iran, the frequency of
sabA was reported as 86.6%, 83.6%, and 100%, respectively,
with no association with the severity of clinical outcomes
(32-34), and this was in line with the current findings and
another study from Japan (29). In comparison with the
above-mentioned studies from different countries, the cur-
rent results showed a considerably lower rate of sabA. This
issue highlights that sabA genetically varies among differ-
ent strains and geographic areas (30), and might not be
present in allH. pylori isolates (14). On the other hand, to es-
tablish an association between H. pylori virulence determi-
nants and clinical outcome, patient selection is crucial be-
cause the studied participants should be sufficiently large
and heterogeneous (35).
5.1. Conclusions
Consistent with most other studies, the rate of hopQI
in the current study was higher than hopQII; however, sabA
frequency in contrast to other reports was considerably
low. Taken together, regarding the heterogeneity of H. py-
lori isolates and diverse results from different geographic
areas, further intensive studies are needed to assess the
role of the above-mentioned genes in H. pylori pathogen-
esis and their association with clinical outcomes in Iran.
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